58. 肥大型心筋症 Hypertrophic cardiomyopathy Clinical trials / Disease details


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-000029-29-NL
(EUCTR)
11/12/201811/12/2018Extra energy for hearts with a genetic defect: ENERGY trialExtra energy for hearts with a genetic defect: ENERGY trial - ENERGY Hypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Vastarel
Product Name: Vastarel
VU University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2Netherlands
2EUCTR2011-000038-12-GB
(EUCTR)
13/09/201117/08/2011Trimetazidine therapy in Hypertrophic CardiomyopathyA Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathy Hypertrophic cardiomyopathy (non-obstructive)
MedDRA version: 16.1;Level: PT;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Vastarel 20mg film coated tablets
Product Name: Trimetazidine Dihydrochloride 20mg
Product Code: not applicable
INN or Proposed INN: trimetazidine dihydrochloride
Other descriptive name: 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride
University College London (UCL)NULLNot RecruitingFemale: yes
Male: yes
Phase 2United Kingdom